Zhang Tao, Wang Xing, Gao Ying
Second Department of Infectious Liver Diseases, First Affiliated Hospital of Xinjiang Medical University Urumqi 830054, Xinjiang, China.
Digestvie Intervention Department, Xi'an International Medical Center Hospital Xi'an 710000, Shaanxi, China.
Am J Transl Res. 2025 May 15;17(5):3538-3545. doi: 10.62347/HWOV2961. eCollection 2025.
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. Due to its insidious onset and nonspecific clinical manifestations, most patients are diagnosed at an advanced stage and are no longer candidates for curative surgical resection. Treatment options for advanced HCC remain limited. Immunotherapy, particularly immune checkpoint inhibitors, in combination with anti-angiogenic agents, has emerged as a promising therapeutic strategy. Several studies have demonstrated the safety and efficacy of apatinib combined with camrelizumab in various solid tumors; however, complete remission is rarely reported. This report presents two cases of Barcelona Clinic Liver Cancer (BCLC) stage C HCC that achieved complete remission following treatment with apatinib plus camrelizumab. According to the Response Evaluation Criteria in Solid Tumors, both patients achieved complete response, allowing for drug discontinuation.
肝细胞癌（HCC）是全球癌症相关死亡的第四大主要原因。由于其发病隐匿且临床表现不具特异性，大多数患者在晚期才被诊断出来，不再是根治性手术切除的候选对象。晚期HCC的治疗选择仍然有限。免疫疗法，特别是免疫检查点抑制剂，与抗血管生成药物联合使用，已成为一种有前景的治疗策略。多项研究已证明阿帕替尼联合卡瑞利珠单抗在各种实体瘤中的安全性和有效性；然而，完全缓解的情况很少被报道。本报告介绍了两例巴塞罗那临床肝癌（BCLC）C期HCC患者，在接受阿帕替尼加卡瑞利珠单抗治疗后实现了完全缓解。根据实体瘤疗效评价标准，两名患者均达到完全缓解，可停药。
